NCT06090799

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 Following Single Intravenous Administration in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, double-blind, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3032 in healthy adults.

Conditions

• Prevention of Graft Rejection After Organ Transplantation

Interventions

Type	Name	Description
DRUG	SHR-3032	Single dose at varying dosage levels depending on treatment assignment
DRUG	SHR-3032 Placebo	Single dose at varying dosage levels depending on treatment assignment

Timeline

• Start date: 2023-11-29
• Primary completion: 2024-03-28
• Completion: 2024-04-08
• First posted: 2023-10-19
• Last updated: 2024-10-15

Locations

1 site across 1 country: China